Özgür Özyılkan

10.6k total citations
115 papers, 792 citations indexed

About

Özgür Özyılkan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Özgür Özyılkan has authored 115 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 30 papers in Surgery. Recurrent topics in Özgür Özyılkan's work include Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Advanced Breast Cancer Therapies (11 papers). Özgür Özyılkan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Advanced Breast Cancer Therapies (11 papers). Özgür Özyılkan collaborates with scholars based in Türkiye, United States and Spain. Özgür Özyılkan's co-authors include Fatih Köse, Ahmet Sezer, Hüseyin Mertsoylu, Ali Ayberk Beşen, Ahmet Taner Sümbül, Erkan Topkan, Umut Dişel, Hüseyin Abalı, Gülten Tekuzman and Uğur Selek and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Özgür Özyılkan

107 papers receiving 764 citations

Peers

Countries citing papers authored by Özgür Özyılkan

Since Specialization

Citations

This map shows the geographic impact of Özgür Özyılkan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Özgür Özyılkan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Özgür Özyılkan more than expected).

Fields of papers citing papers by Özgür Özyılkan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Özgür Özyılkan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Özgür Özyılkan. The network helps show where Özgür Özyılkan may publish in the future.

Co-authorship network of co-authors of Özgür Özyılkan

This figure shows the co-authorship network connecting the top 25 collaborators of Özgür Özyılkan. A scholar is included among the top collaborators of Özgür Özyılkan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Özgür Özyılkan. Özgür Özyılkan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial 2025 ·Journal of Thoracic Oncology ·(unknown), L. Paz-Ares, Hakan Harputluoğlu, (unknown), Sérgio Rossi, (unknown), Carole Hélissey, (unknown), (unknown), Mehmet Alı Nahıt Şendur, M. D’Arcangelo, (unknown), (unknown), Özgür Özyılkan, (unknown), Marina Celanovic, (unknown), (unknown)	0
2	Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy 2024 ·European Urology ·Vadim S. Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, Andrey Semenov, Özgür Özyılkan, Yu‐Li Su, Jóse Ángel Arranz Arija, Masao Tsujihata, Martin Bögemann, Mathijs P. Hendriks, (unknown), Eli Rosenbaum, Karla Alejandra Lopez, Abhishek Bavle, Chih‐Chin Liu, (unknown), (unknown)	1
3	LBA2 SKYSCRAPER-06: Efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC) 2024 ·Immuno-Oncology Technology ·(unknown), (unknown), Daniel J. Lee, (unknown), (unknown), Christine M. Lovly, Özgür Özyılkan, Q. Li, Melissa L. Johnson, (unknown), (unknown), (unknown), Jorge Alatorre-Alexander, (unknown), Isabelle Rooney, Sarah Troutman, Xiaohui Wen, Namrata S. Patil, Wei Zou, Rolf A. Stahel	5
4	Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study 2023 ·Cancer Medicine ·Likun Chen, (unknown), Timuçin Çil, (unknown), İrfan Çiçin, Yihong Shen, Zhihua Liu, Özgür Özyılkan, (unknown), Jun Chen, (unknown), Zhendong Chen, Helong Zhang, (unknown), Qingfeng Dong, (unknown), Jin‐Chen Yu, Li Zhang	3
5	Pertuzumab-mediated Cardiotoxicity: A Single Center Study. 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Ahmet Taner Sümbül, Ahmet Sezer, Şenol Demircan, Haldun Müderrisoğlu, Özgür Özyılkan	0
6	Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis 2021 ·Journal of Oncology ·Erkan Topkan, Uğur Selek, Ahmet Küçük, (unknown), Yurday Özdemir, Duygu Sezen, Hüseyin Mertsoylu, Ali Ayberk Beşen, Yasemin Bölükbaşı, Özgür Özyılkan, Berrin Pehlivan	13
7	Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study 2021 ·The Turkish Journal of Gastroenterology ·Ulus Salih Akarca, Belkıs Ünsal, Orhan Sezgın, Kendal Yalçın, Meral Akdoğan, Can Gönen, Feyza Gündüz, Seren Özeni̇rler, Abdullah Sonsuz, Dinc Dinçer, Salim Başol Tekin, İdris Yücel, Hakan Akbulut, Canan Alkım, Özgür Özyılkan, (unknown), (unknown), Ramazan Idılman, (unknown), (unknown)	2
8	273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer 2020 ·Annals of Oncology ·Erika Hamilton, Javier Cortés, Özgür Özyılkan, (unknown), Katarína Petráková, Alexey Manikhas, Guy Jérusalem, Roberto Hegg, Jens Huober, Sonya C. Chapman, Zhengyu Yang, (unknown), (unknown), Miguel Martín	5
9	A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study 2018 ·OncoTargets and Therapy ·Şuayib Yalçın, Ramazan Yıldız, Faysal Dane, Aziz Karaoğlu, Berna Öksüzoğlu, Özgür Özyılkan, Alper Sevinç, Feyyaz Özdemir, Hande Turna, Rüçhan Uslu, (unknown)	2
10	Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit? 2015 ·Medical Oncology ·(unknown), Fatih Köse, Ahmet Taner Sümbül, (unknown), Ali Ayberk Beşen, Ali Murat Tatlı, Hüseyin Mertsoylu, Ahmet Sezer, (unknown), Özgür Özyılkan, Hüseyin Abalı	3
11	Lack of Prognostic Significance of C-erbB-2 Expression in Low- and High- grade Astrocytomas 2014 ·Asian Pacific Journal of Cancer Prevention ·(unknown), Ali Ayberk Beşen, (unknown), Hüseyin Mertsoylu, Ali Arıcan, Fazi̇let Kayaselçuk, Özgür Özyılkan	6
12	Primary Extranodal Non-Hodgkin's Lymphoma: Clinicopathological Features, Survival and Treatment Outcome in Two Cancer Centers of Southern Turkey 2014 ·Asian Pacific Journal of Cancer Prevention ·Hüseyin Mertsoylu, (unknown), Ali Ayberk Beşen, (unknown), Ahmet Sezer, (unknown), Fatih Köse, Ali Arıcan, Özgür Özyılkan	7
13	Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study 2012 ·Medical Oncology ·Umut Dişel, Ali Ayberk Beşen, (unknown), Hüseyin Mertsoylu, Ahmet Sezer, Fatih Köse, Ahmet Taner Sümbül, (unknown), (unknown), Hüseyin Abalı, Özgür Özyılkan	8
14	Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation 2010 ·Lung Cancer ·Umut Dişel, Serdar Öztuzcu, Ali Ayberk Beşen, (unknown), Fatih Köse, Ahmet Taner Sümbül, Ahmet Sezer, (unknown), Hüseyin Abalı, Özgür Özyılkan	26
15	Primary Renal Lymphoma: Report of Four Cases 2009 ·Oncology Research and Treatment ·Fatih Köse, (unknown), Hüseyin Mertsoylu, Ahmet Sezer, N. Emrah Koçer, Naime Tokmak, Ferhat Kılınç, Özgür Özyılkan	17
16	Hodgkin′s disease in an elderly patient with B-Cell chronic lymphocytic leukemia 2005 ·Indian Journal of Cancer ·(unknown), Özgür Özyılkan, (unknown), Banu Bilezikçi	2
17	Primary thyroid lymphoma: report of two cases 2004 ·East African Medical Journal ·(unknown), (unknown), Turgut Noyan, Fazi̇let Kayaselçuk, Özgür Özyılkan	5
18	Tamoxifen-Induced Cirrhotic Process 2001 ·The Breast Journal ·(unknown), Şahika Zeynep Akı, Özgür Özyılkan, (unknown)	4
19	Original Articles : Imipenem - Cilastatin versus Sulbactam - Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients 1999 ·The Korean Journal of Internal Medicine ·Özgür Özyılkan, (unknown), (unknown)	1
20	Imipenem - Cilastatin versus Sulbactam - Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients 1999 ·The Korean Journal of Internal Medicine ·Özgür Özyılkan, (unknown), (unknown)	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact